Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beautycounter On 'National Radar' With Regulatory Reform Mission

Executive Summary

Upping its bid to disrupt the cosmetics market, Beautycounter hosted a congressional briefing Nov. 17 to advocate stronger industry oversight, putting its weight behind the Personal Care Products Safety Act in particular. The direct seller, which has self-banned 1,500 ingredients from its offerings, has seen its sales and following grow rapidly since launching less than three years ago and aligning itself with leading NGOs.

Advertisement

Related Content

Beautycounter-Led Coalition Lobbies For Tighter Cosmetics Regulations
FDA’s 10ppm Cosmetic Lead Limit Criticized, Including By Industry Player
'EWG Verified' Personal-Care Safety Seal Builds On 'Skin Deep' Platform
Honest Company To Launch Color Cosmetics On Back Of $100 Mil. Financing
Avon Counting On 'Beauty For A Purpose' To Inspire Reps, Consumers
In Brief: Prop 65 Aloe Vera Listing Update; Beautycounter Sales Soar; More
Advertisement
UsernamePublicRestriction

Register

RS019760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel